AXL and lung adenocarcinoma: Bemcentinib (BGB324), a specific type I kinase inhibitor of Axl with promising preclinical results [53] has entered clinical trials for cancers including non-small cell lung carcinoma, adenocarcinoma of the lung, acute myeloid leukemia, melanoma and pancreatic cancer (obtained from ClinicalTrials.gov).